Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT

IF 20.1 1区 医学 Q1 ONCOLOGY Cancer Communications Pub Date : 2024-07-08 DOI:10.1002/cac2.12582
Rolf F. Barth, Nilendu Gupta, Shinji Kawabata
{"title":"Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT","authors":"Rolf F. Barth,&nbsp;Nilendu Gupta,&nbsp;Shinji Kawabata","doi":"10.1002/cac2.12582","DOIUrl":null,"url":null,"abstract":"<p>Boron neutron capture therapy (BNCT) is a cancer treatment modality based on the nuclear capture and fission reactions that occur when boron-10, a stable isotope, is irradiated with neutrons of the appropriate energy to produce boron-11 in an unstable form, which undergoes instantaneous nuclear fission to produce high-energy, tumoricidal alpha particles. The primary purpose of this review is to provide an update on the first drug used clinically, sodium borocaptate (BSH), by the Japanese neurosurgeon Hiroshi Hatanaka to treat patients with brain tumors and the second drug, boronophenylalanine (BPA), which first was used clinically by the Japanese dermatologist Yutaka Mishima to treat patients with cutaneous melanomas. Subsequently, BPA has become the primary drug used as a boron delivery agent to treat patients with several types of cancers, specifically brain tumors and recurrent tumors of the head and neck region. The focus of this review will be on the initial studies that were carried out to define the pharmacokinetics and pharmacodynamics of BSH and BPA and their biodistribution in tumor and normal tissues following administration to patients with high-grade gliomas and their subsequent clinical use to treat patients with high-grade gliomas. <i>First</i>, we will summarize the studies that were carried out in Japan with BSH and subsequently at our own institution, The Ohio State University, and those of several other groups. <i>Second</i>, we will describe studies carried out in Japan with BPA and then in the United States that have led to its use as the primary drug that is being used clinically for BNCT. <i>Third</i>, although there have been intense efforts to develop new and better boron delivery agents for BNCT, none of these have yet been evaluated clinically. The present report will provide a guide to the future clinical evaluation of new boron delivery agents prior to their clinical use for BNCT.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"44 8","pages":"893-909"},"PeriodicalIF":20.1000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12582","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12582","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Boron neutron capture therapy (BNCT) is a cancer treatment modality based on the nuclear capture and fission reactions that occur when boron-10, a stable isotope, is irradiated with neutrons of the appropriate energy to produce boron-11 in an unstable form, which undergoes instantaneous nuclear fission to produce high-energy, tumoricidal alpha particles. The primary purpose of this review is to provide an update on the first drug used clinically, sodium borocaptate (BSH), by the Japanese neurosurgeon Hiroshi Hatanaka to treat patients with brain tumors and the second drug, boronophenylalanine (BPA), which first was used clinically by the Japanese dermatologist Yutaka Mishima to treat patients with cutaneous melanomas. Subsequently, BPA has become the primary drug used as a boron delivery agent to treat patients with several types of cancers, specifically brain tumors and recurrent tumors of the head and neck region. The focus of this review will be on the initial studies that were carried out to define the pharmacokinetics and pharmacodynamics of BSH and BPA and their biodistribution in tumor and normal tissues following administration to patients with high-grade gliomas and their subsequent clinical use to treat patients with high-grade gliomas. First, we will summarize the studies that were carried out in Japan with BSH and subsequently at our own institution, The Ohio State University, and those of several other groups. Second, we will describe studies carried out in Japan with BPA and then in the United States that have led to its use as the primary drug that is being used clinically for BNCT. Third, although there have been intense efforts to develop new and better boron delivery agents for BNCT, none of these have yet been evaluated clinically. The present report will provide a guide to the future clinical evaluation of new boron delivery agents prior to their clinical use for BNCT.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
硼aptate钠(BSH)和硼苯丙氨酸(BPA)作为硼输送剂用于癌症中子俘获疗法(NCT)的评估:NCT新硼输送剂的最新进展和未来临床评估指南。
硼中子俘获疗法(BNCT)是一种基于核俘获和裂变反应的癌症治疗方法,当稳定同位素硼-10被适当能量的中子照射后,会产生不稳定形式的硼-11,而硼-11会瞬间发生核裂变,产生高能量、具有肿瘤杀伤力的α粒子。本综述的主要目的是介绍日本神经外科医生畑中浩(Hiroshi Hatanaka)在临床上使用的第一种药物硼硫酸钠(BSH)治疗脑肿瘤患者的最新情况,以及日本皮肤科医生三岛由贵(Yutaka Mishima)在临床上首次使用的第二种药物硼苯丙氨酸(BPA)治疗皮肤黑色素瘤患者的最新情况。随后,BPA 成为治疗多种类型癌症(尤其是脑肿瘤和头颈部复发性肿瘤)患者的主要硼输送药物。本综述的重点是为确定 BSH 和 BPA 的药代动力学和药效学而开展的初步研究,以及它们在高级别胶质瘤患者用药后在肿瘤和正常组织中的生物分布和随后用于治疗高级别胶质瘤患者的临床应用。首先,我们将总结在日本进行的 BSH 研究,以及随后在我们自己的研究机构俄亥俄州立大学和其他几个研究小组进行的研究。其次,我们将介绍在日本开展的 BPA 研究以及随后在美国开展的研究,这些研究促使 BPA 成为临床上用于 BNCT 的主要药物。第三,尽管人们一直在努力为 BNCT 研发新的、更好的硼给药剂,但这些药物都尚未经过临床评估。本报告将为今后新的硼给药剂在临床用于 BNCT 之前的临床评估提供指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
期刊最新文献
Anti-tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards. Issue Information Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma. Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes. Discovery of a novel viroid-like circular RNA in colorectal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1